IP Library Granted Patent US 8,862,239
Granted Patent B2
US 8,862,239 · App. 14/037,230 · Granted Oct 14, 2014

Selective high frequency spinal cord modulation for inhibiting pain with reduced side effects, and associated systems and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,862,239
App. No.
14/037,230
Granted
Oct 14, 2014
Kind
B2
Abstract

Selective high-frequency spinal cord modulation for inhibiting pain with reduced side effects and associated systems and methods are disclosed. In particular embodiments, high-frequency modulation in the range of from about 1.5 KHz to about 50 KHz may be applied to the patient's spinal cord region to address low back pain without creating unwanted sensory and/or motor side effects. In other embodiments, modulation in accordance with similar parameters can be applied to other spinal or peripheral locations to address other indications.

Claims (49)

1. A spinal cord modulation system for reducing or eliminating pain in a patient, the system comprising:

a voltage-controlled pulse generator configured to generate a non-paresthesia-producing therapy signal, wherein at least a portion of the therapy signal is at a frequency in a frequency range from 1.5 kHz to 100 kHz; and

an implantable signal delivery device electrically coupled to the pulse generator and configured to deliver the therapy signal to the patient's spinal cord.

2. The system of claim 1 , wherein the pulse generator generates the therapy signal at a duty cycle.

3. The system of claim 2 , wherein the duty cycle is 50-100%.

4. The system of claim 1 , wherein the frequency range is from 1.5 kHz to 50 kHz.

5. The system of claim 1 , wherein the frequency range is from 3 kHz to 20 kHz.

6. The system of claim 1 , wherein at least a portion of the therapy signal is at a frequency of 10 kHz.

7. The system of claim 1 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 10 microseconds to 333 microseconds.

8. The system of claim 1 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 25 microseconds to 166 microseconds.

9. The system of claim 1 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 30 microseconds to 35 microseconds.

10. The system of claim 1 wherein the pulse generator is an external pulse generator.

11. The system of claim 1 wherein the pulse generator is an implantable pulse generator.

12. The system of claim 1 , wherein the pulse generator includes a constant voltage arrangement.

13. The system of claim 1 , wherein the implantable signal delivery device is a percutaneous lead configured to be implanted in the patient's epidural space.

14. The system of claim 1 , wherein the implantable signal delivery device is a paddle lead configured to be implanted proximate a target location.

15. A spinal cord stimulation system for reducing or eliminating pain in a patient, the system comprising:

a voltage-controlled implantable signal generator configured to generate a non-paresthesia-producing therapy signal, wherein at least a portion of the therapy signal is at a frequency in a frequency range from 3 kHz to 20 kHz, and wherein the implantable signal generator includes a constant voltage arrangement; and

a signal delivery device electrically coupled to the implantable signal generator and configured to deliver the therapy signal to the patient's spinal cord.

16. The system of claim 15 , wherein the implantable signal generator delivers the therapy signal at a duty cycle.

17. The system of claim 16 , wherein the duty cycle is 50-100%.

18. The system of claim 16 , wherein the frequency in the frequency range from 3 kHz to 20 kHz is applied throughout the length of an on-period in the duty cycle.

19. The system of claim 16 , wherein the frequency in the frequency range from 3 kHz to 20 kHz is applied during a portion of an on-period in the duty cycle.

20. The system of claim 15 , wherein the signal delivery device is a percutaneous lead configured to be implanted in the patient's epidural space proximate to a target location.

21. The system of claim 20 , wherein the target location is a vertebral location within a range from T9-T12.

22. The system of claim 20 , wherein the target location is a vertebral location within a range from T9-T10.

23. The system of claim 15 , wherein at least a portion of the therapy signal is at a frequency of 10 kHz.

24. The system of claim 15 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 10 microseconds to 333 microseconds.

25. The system of claim 15 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 25 microseconds to 166 microseconds.

26. The system of claim 15 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 30 microseconds to 35 microseconds.

27. A spinal cord modulation system for reducing or eliminating back or leg pain in a patient, without relying on paresthesia or tingling to mask the patient's sensation of the pain, the system comprising:

an implantable signal generator having a housing and one or more processors disposed within the housing, wherein the one or more processors are configured to generate a non-paresthesia-producing therapy signal with a constant voltage arrangement, wherein at least a portion of the therapy signal is at a frequency in a frequency range from 1.5 kHz to 50 kHz; and

an elongated electrical lead electrically coupled to the implantable signal generator and configured to be implanted in the patient's epidural space, wherein the electrical lead includes two or more electrodes configured to deliver the therapy signal to the patient's spinal cord.

28. The system of claim 27 , wherein the implantable signal generator generates the therapy signal at a duty cycle.

29. The system of claim 28 , wherein the duty cycle is 50-100%.

30. The system of claim 28 , wherein the frequency in the frequency range from 1.5 kHz to 50 kHz is applied throughout the length of an on-period in the duty cycle.

31. The system of claim 28 , wherein the frequency in the frequency range from 1.5 kHz to 50 kHz is applied during a portion of an on-period in the duty cycle.

32. The system of claim 27 , wherein the frequency range is from 3 kHz to 20 kHz.

33. The system of claim 27 , wherein at least a portion of the therapy signal is at a frequency of 10 kHz.

34. The system of claim 27 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 10 microseconds to 333 microseconds.

35. The system of claim 27 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 25 microseconds to 166 microseconds.

36. The system of claim 27 wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range from 30 microseconds to 35 microseconds.

37. A spinal cord modulation system for reducing or eliminating pain in a patient, comprising:

a voltage-controlled implantable pulse generator having a constant voltage arrangement and machine-readable medium containing instructions for generating and transmitting a spinal modulation signal that at least partially reduces the patient's sensation of pain without relying on paresthesia or tingling to mask the patient's sensation of the pain, wherein at least a portion of the spinal modulation signal is at a frequency in a frequency range from 3 kHz to 20 kHz, and has a pulse width in a pulse width range from 25 microseconds to 166 microseconds; and

an implantable lead electrically coupled to the implantable pulse generator, wherein the electrical lead includes two or more electrodes configured to deliver the transmitted spinal modulation signal to a target location in the patient's spinal cord.

38. The system of claim 37 , wherein at least a portion of the therapy signal is at a frequency of 10 kHz.

39. The system of claim 37 , wherein the portion of the therapy signal includes pulses having a pulse width in a pulsewidth range between 30 microseconds and 35 microseconds.

40. The system of claim 37 , wherein the target location is a vertebral location within a range from T9-T12.

41. The system of claim 37 , wherein the target location is a vertebral location within a range from T9-T10.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2021
From: CEPHAS CAPITAL PARTNERS II, L.P.
To: PHARMA-SMART INTERNATIONAL, INC.; SARKIS HOLDINGS, INC.; SARKIS HOLDINGS II, INC.
Reel/Frame 056560/0206 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA NAME PREVIOUSLY RECORDED ON REEL 031281 FRAME 0704. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 21, 2016
From: ALATARIS, KONSTANTINOS; WALKER, ANDRE B.; PARKER, JON; CHITRE, YOUGANDH; PARK, SANGSOO WESLEY; THACKER, JAMES R.
To: NEVRO CORP.
Reel/Frame 040661/0087 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2016
From: CRG SERVICING LLC
To: NEVRO CORP.
Reel/Frame 039168/0890 →
ASSIGNMENT AGREEMENT (REAFFIRMATION) Recorded Jun 13, 2016
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: CRG SERVICING LLC,
Reel/Frame 038984/0865 →
SECURITY INTEREST Recorded Dec 12, 2014
From: NEVRO CORP.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 034619/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2013
From: ALATARIS, KONSTANTINOS; WALKER, ANDRE B.; PARKER, JON; CHITRE, YOUGANDH; PARK, SANGSOO WESLEY; THACKER, JAMES R.
To: NEVRO CORPORATION
Reel/Frame 031281/0704 →